Prevalence of β-lactamase-encoding genes among Enterobacteriaceae bacteremia isolates collected in 26 U.S. hospitals: report from the SENTRY Antimicrobial Surveillance Program (2010).
about
Beyond Susceptible and Resistant, Part III: Treatment of Infections due to Gram-Negative Organisms Producing CarbapenemasesOverview of ESBL-producing Enterobacteriaceae from a Nordic perspectiveThe Epidemiology of Carbapenem-Resistant Enterobacteriaceae: The Impact and Evolution of a Global Menace.Epidemiology and clinical outcomes of patients with carbapenem-resistant Klebsiella pneumoniae bacteriuria.The Pandemic H30 Subclone of Sequence Type 131 (ST131) as the Leading Cause of Multidrug-Resistant Escherichia coli Infections in the United States (2011-2012).Phenotypic and molecular characteristics of carbapenem-resistant Enterobacteriaceae in a health care system in Los Angeles, California, from 2011 to 2013.Rapid testing using the Verigene Gram-negative blood culture nucleic acid test in combination with antimicrobial stewardship intervention against Gram-negative bacteremia.A statistical approach for determination of disk diffusion-based cutoff values for systematic characterization of wild-type and non-wild-type bacterial populations in antimicrobial susceptibility testing.Ceftazidime-avibactam activity tested against Enterobacteriaceae isolates from U.S. hospitals (2011 to 2013) and characterization of β-lactamase-producing strains.Recent Emergence of Escherichia coli with Cephalosporin Resistance Conferred by blaCTX-M on Washington State Dairy FarmsCarbapenem-Resistant Enterobacteriaceae in Children, United States, 1999-2012.Clinical and microbiologic characteristics of cefotaxime-non-susceptible Enterobacteriaceae bacteremia: a case control study.Comparison of 2 chromogenic media for the detection of extended-spectrum β-lactamase producing Enterobacteriaceae stool carriage in nursing home residents.Klebsiella pneumoniae Isolate from a New York City Hospital Belonging to Sequence Type 258 and Carrying blaKPC-2 and blaVIM-4.β-Lactamase Characterization of Gram-Negative Pathogens Recovered from Patients Enrolled in the Phase 2 Trials for Ceftazidime-Avibactam: Clinical Efficacies Analyzed against Subsets of Molecularly Characterized Isolates.Antimicrobial Activities of Ceftazidime-Avibactam and Comparator Agents against Gram-Negative Organisms Isolated from Patients with Urinary Tract Infections in U.S. Medical Centers, 2012 to 2014.Changes in the Frequencies of β-Lactamase Genes among Enterobacteriaceae Isolates in U.S. Hospitals, 2012 to 2014: Activity of Ceftazidime-Avibactam Tested against β-Lactamase-Producing Isolates.Effect of the β-Lactamase Inhibitor Vaborbactam Combined with Meropenem against Serine Carbapenemase-Producing Enterobacteriaceae.[Prevalence and risk factors for extended-spectrum β-lactamase-producing Escherichia coli causing community-onset urinary tract infections in Colombia].Determining a clinical framework for use of cefepime and β-lactam/β-lactamase inhibitors in the treatment of infections caused by extended-spectrum-β-lactamase-producing Enterobacteriaceae.Querying automated antibiotic susceptibility testing instruments: a novel population-based active surveillance method for multidrug-resistant gram-negative bacilli.Antimicrobial activity of ceftazidime-avibactam against Gram-negative organisms collected from U.S. medical centers in 2012.Examining the Clinical Effectiveness of Non-Carbapenem β-Lactams for the Treatment of Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae.Pharmacokinetics-Pharmacodynamics of a Novel β-Lactamase Inhibitor, CB-618, in Combination with Meropenem in an In Vitro Infection Model.Updates in the Management of Cephalosporin-Resistant Gram-Negative Bacteria.Antibiotic resistance in wastewater: occurrence and fate of Enterobacteriaceae producers of class A and class C β-lactamases.Post-β-lactamase-inhibitor effect of tazobactam in combination with ceftolozane on extended-spectrum-β-lactamase-producing strains.WCK 5222 (cefepime/zidebactam) antimicrobial activity tested against Gram-negative organisms producing clinically relevant β-lactamases.Plasmid-mediated resistance to cephalosporins and quinolones in Escherichia coli from American crows in the USA.WCK 5222 (Cefepime-Zidebactam) Antimicrobial Activity against Clinical Isolates of Gram-Negative Bacteria Collected Worldwide in 2015.Arbekacin activity against contemporary clinical bacteria isolated from patients hospitalized with pneumonia.Ceftaroline activity against bacterial pathogens frequently isolated in U.S. medical centers: results from five years of the AWARE surveillance program.Mutation-driven β-lactam resistance mechanisms among contemporary ceftazidime-nonsusceptible Pseudomonas aeruginosa isolates from U.S. hospitals.Contemporary diversity of β-lactamases among Enterobacteriaceae in the nine U.S. census regions and ceftazidime-avibactam activity tested against isolates producing the most prevalent β-lactamase groupsHigh Rates of Nonsusceptibility to Ceftazidime-avibactam and Identification of New Delhi Metallo-β-lactamase Production in Enterobacteriaceae Bloodstream Infections at a Major Cancer Center.Extended-Spectrum β-lactam Resistance in the Enteric Flora of Patients at a Tertiary Care Medical Centre.Kinetics of Sulbactam Hydrolysis by β-Lactamases, and Kinetics of β-Lactamase Inhibition by Sulbactam.Unusual carbapenem resistant but ceftriaxone and cefepime susceptible Klebsiella oxytoca isolated from a blood culture: Case report and whole-genome sequencing investigation.Incidence rates of carbapenemase-producing Enterobacteriaceae clinical isolates in France: a prospective nationwide study in 2011-12.Activity of Ceftolozane-Tazobactam Tested against Pseudomonas aeruginosa and Enterobacteriaceae Isolates Collected from Respiratory Tract Specimens of Hospitalized Patients in the United States During 2013 to 2015.
P2860
Q26747580-208C0DEC-D800-4FF1-96D9-132732239D6DQ27026917-60958465-E689-465C-8D25-97D4D6EC8BFEQ30234957-F66DB209-F84E-4227-94F7-2A81251931A4Q33798101-1F7D066C-2692-4D88-99ED-B40ABE4AD72AQ33806382-3A427A15-E0C5-419C-B5B3-7B9E81DB91B5Q35036037-8B05D114-67C9-426A-BBDC-F3A65CACEA9FQ35076892-1F1F25E3-298A-4F85-AAD2-364851B27DAAQ35607484-02C560FD-8BE7-4136-825D-0ACD3E4A4AC1Q35607885-C2221751-5DFD-4C8E-83FE-D7769745ACA9Q35764110-F75ED10E-4E7B-4747-8238-912093F51EE4Q36212092-198FC7E0-2BAF-41AF-8021-46D35A085FF9Q36243340-16AA4145-155E-494A-A484-EC610C445F13Q36624362-7F90B0C0-2D9F-49BA-B592-2C436E18EFE3Q36644751-E22EEC79-B800-4D45-96F2-9669CD44F22FQ36644786-C2736319-2797-48D4-80F4-CC05E8F3C03AQ37023324-6C657810-B056-4AEB-9BE7-ED7FCF86DD51Q37120191-991E7F14-8ADE-44C5-8A5F-1A3C5EF8DF05Q37203731-9871F78D-890B-4CE1-8A13-C54A0A3DE4FEQ37334691-5F1CFA11-959A-4480-B263-697B68CA463DQ38165138-31118E1F-40CA-461D-AC04-889A3E230FF4Q38193970-213D53A5-793C-4802-BC9F-783FDE3ED32EQ38325959-C42CE0FB-40CB-4CA2-83F9-CCE1AE5C9741Q38792841-38B203EA-B90A-44C1-A236-933DA76AF76FQ38891891-ECC454C3-5EB4-45EC-84E0-D32CCC699EFFQ38981397-BD4DC6FC-65C1-4B3C-8749-B4D7CCE22304Q39092050-303081A7-C377-40A0-89AC-16D560BC8444Q39683724-BEADE705-90B4-4091-853B-1AF1E3DD35A4Q40281991-33BAF665-736B-4012-8392-09704A32AC9AQ40301586-B288373B-0F6C-4F9D-BAFC-B10A5FFBBE75Q40315393-2F221FE3-0C02-41E2-A8EB-EF5B815B3888Q40675239-D2BAD37A-C7A5-4476-8E4F-68461374A1DDQ41507443-3884A666-7E40-46CB-96EC-3C20081523EBQ41757275-D04B23B5-6A4E-4EDC-8AD4-D5D1597A3678Q41907738-A1F319E6-FBE0-4FA8-8EA0-AD9DBE6D7362Q42102553-C0164FD0-522B-469B-8703-A1BC9CD7046BQ43173361-AFCE715F-DF76-4DD9-8D78-548CEEAF839FQ46296415-F677A0A4-E838-4962-B9E1-A2E9A7EB1C31Q46560124-FF21D273-203B-4182-AAC6-7D9E5D4FF668Q46877738-9B323A23-42D4-4D31-A565-7F67B2066FA1Q47675324-36D3B76D-9EA6-4DF7-A630-642783141713
P2860
Prevalence of β-lactamase-encoding genes among Enterobacteriaceae bacteremia isolates collected in 26 U.S. hospitals: report from the SENTRY Antimicrobial Surveillance Program (2010).
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Prevalence of β-lactamase-enco ...... l Surveillance Program (2010).
@en
type
label
Prevalence of β-lactamase-enco ...... l Surveillance Program (2010).
@en
prefLabel
Prevalence of β-lactamase-enco ...... l Surveillance Program (2010).
@en
P2093
P2860
P356
P1476
Prevalence of β-lactamase-enco ...... l Surveillance Program (2010).
@en
P2093
Lalitagauri M Deshpande
Rodrigo E Mendes
Ronald N Jones
Sarah E Farrell
P2860
P304
P356
10.1128/AAC.02252-12
P407
P577
2013-04-15T00:00:00Z